Published • loading... • Updated
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Kevin Ali resigned after an internal probe found improper sales practices for Nexplanon, accounting for under 1% of revenue but leading to inaccurate company statements.
- Shortly, Kevin Ali agreed to step down after an audit committee probe found some U.S. wholesalers were asked to buy excess Nexplanon across several quarters between 2022 and 2025.
- Inventory-Management exceptions allowed U.S. wholesalers to accept larger shipments and earn incentive fees, with over-purchases under 1% of Organon's consolidated revenue for 2022 and 2024 helping meet guidance.
- Investing.com reported the stock plunged 18% after the resignation was announced, and Organon terminated its Head of U.S. Commercial & Government Affairs while saying Kevin Ali will not receive severance or equity-related retirement benefits.
- The board named Joseph Morrissey interim CEO, with an SEC filing showing a $1 million salary boost, a restricted stock award, and a bonus increase to 100%, while Carrie S. Cox and Robert Essner assume additional roles.
- Shortly after a UK code breach finding, Organon said, 'While the findings to date do not necessitate a restatement or revision to any previously issued financial statements, the company is taking remedial actions to improve its financial controls and address any material weaknesses', and noted prior statements were judged inaccurate or incomplete.
Insights by Ground AI
10 Articles
10 Articles
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Organon said on Monday CEO Kevin Ali will resign from his role, after an internal investigation into sales of its Nexplanon contraceptive implant to wholesalers pointed to "improper" practices.
·London, United Kingdom
Read Full Article
Organon CEO Resigns After Probe Finds Improper Sales Practices
The chief executive of Organon, the company behind the birth control implant product Nexplanon, has stepped down after an audit committee uncovered improper sales practices related to the medicine.
·New York, United States
Read Full ArticleCoverage Details
Total News Sources10
Leaning Left0Leaning Right1Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
C 86%
14%
Factuality
To view factuality data please Upgrade to Premium
